Drug Database
Back to search

Belgium· BE-AMP-SAM562506-00

Zolgensma 2 10*13 vg/ml

A onasemnogene abeparvovec product containing onasemnogene abeparvovec, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.

ATC M09AX09

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedZolgensma 2 10*13 vg/mlATCM09AX09REGISTER NO.BE-AMP-SAM562506-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about onasemnogene abeparvovecAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Onasemnogene abeparvovec is registered in 14 of 19 countries.

Countries holding a registration under ATC M09AX09 (onasemnogene abeparvovec), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose
Search onasemnogene abeparvovec products by name

Onasemnogene abeparvovec · ATC M09AX09

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Onasemnogene Abeparvovec
Manufacturer
Novartis Europharm
Country
Belgium (BE)
ATC code
M09AX09
ATC class
Onasemnogene abeparvovec
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7732951
  • be_apb
    4338240

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

19 interactions on record for onasemnogene abeparvovec.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check onasemnogene abeparvovec against other medicinesHow interaction checks work

Onasemnogene abeparvovec · interactions on record

19 records

  • 4 severe
  • 15 moderate

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Onasemnogene abeparvovec in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All onasemnogene abeparvovec products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Itvisma, Zolgensma
  • Liechtenstein · Itvisma, Zolgensma
  • Norway · Itvisma, Zolgensma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e7392502-6813-4bd0-ac47-6a8f5985e499
GET /v1/drugs/e7392502-6813-4bd0-ac47-6a8f5985e499?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Zolgensma 2 10*13 vg/ml",
  "name_fr": "Zolgensma 2 10*13 vg/ml",
  "name_nl": "Zolgensma 2 10*13 vg/ml",
  "amp_code": "SAM562506-00",
  "strengths": [
    "2.0000",
    "2.0000",
    "0.2000"
  ],
  "pack_count": 1,
  "substances": [
    "Onasemnogene Abeparvovec",
    "Sodium"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Onasemnogene Abeparvovec",
  "authorisation_numbers": [
    "EU/1/20/1443/016"
  ]
}
API referenceMCP serverPlans

See everything about onasemnogene abeparvovec.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console